VH4524184
- Generic Name
- VH4524184
A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 26
- Registration Number
- NCT06310616
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 28
- Registration Number
- NCT06214052
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 105
- Registration Number
- NCT05631704
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath